
Amprologix Limited seeks to develop new antimicrobials to tackle the growing threat of antimicrobial resistance (AMR), which is reported to be one of the biggest threats to global health and food security.
Their work stems from the discovery of their lead compound, Epidermicin on the human skin, and has shown potential to be the first novel class of antimicrobials developed since the 1980s.
The additional funds can support ongoing research and development efforts, enabling the company to further investigate and refine its lead compound, Epidermicin NI01.
Overall, the cash injection from a successful R&D tax relief claim would help accelerate the growth of Amprologix Limited, positioning it more competitively in the global market for antimicrobial agents and contributing to the fight against antimicrobial resistance.
Our in-house team of highly experienced scientists, engineers, tax consultants and attorneys would love to answer all your questions and help you make the most out of your R&D efforts.
Contact our R&D Tax Experts